However, the use of SOR in AML patients is quite effective, especially in patients with FLT3-ITD mutation [33], leading to prolonged survival [31], again reinforcing the importance of the RAS/RAF/MEK/ERK signaling pathway. Here, FLT3 is linked to acute myeloid leukemia.